Intriguingly, the therapeutic efficacy of PD-1 checkpoint blockade is robustly attenuated in METTL3-deficient mice, indicating METTL3 as a potential therapeutic target for tumor immunotherapy, including in melanoma (131). Here, METTL3 is linked to neoplasm.